PRE - יחס חוב להיוון בספרים Prenetics

The linear price action on the chart for Prenetics Global (PRE) demonstrates the market quotes of the asset, which is currently valued at 0.01. Prenetics Global generates revenue through the sale of CircleDNA and diagnostic services for clinics and individuals. To minimize bureaucratic barriers, the business attracts corporate clients and insurers. The current priority has shifted toward cost reduction and organic growth rather than mergers.

Selecting sustainable issuers requires an analysis of the total liabilities-to-equity ratio on the balance sheet, which determines the degree of the business's credit protection against default. This financial leverage ratio based on book capitalization measures the company's dependence on borrowed funds, which for Prenetics Global (PRE), during its cost-cutting phase and pivot away from M&A, confirms a transition toward conservative organic growth.